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Evidence-Based Answer
Topical metronidazole and azelaic acid are equally effective for the 
papulopustular lesions of acne rosacea, although metronidazole is better 
tolerated. Oral doxycycline, tetracycline, and metronidazole are also 
effective, but not enough evidence exists to determine whether one is more 
effective than another or more effective than topical therapy (SOR: A, 
 systematic review and individual RCTs). Some evidence supports a benefit 
for topical sodium sulfacetamide with sulfur, and benzoyl peroxide 
(SOR: B, small single RCTs). Pulsed-light and laser therapy may improve 
the erythema and telangiectasias associated with acne rosacea (SOR: C, 
case series). All patients with acne rosacea should use sunscreen and 
emollients, and avoid skin irritants (SOR: C, expert opinion).
Evidence summary
A Cochrane systematic review found that topical metronidazole and 
azelaic acid are both more effective than placebo for patients with 
papulopustular lesions of acne rosacea (TABLE). The authors noted 
that the studies were generally weak because of poor methodology and 
reporting, small sample sizes, and lack of quality-of-life measures (only 
2 RCTs evaluated patient assessment of treatment effectiveness).1
 Another systematic review reported small case series suggesting 
possible effectiveness with topical tretinoin (43 cases), oral clindamycin 
(43 cases), oral erythromycin (13 cases), and topical tacrolimus (3 cases).2
Oral metronidazole and tetracycline also work
The Cochrane systematic review also found that oral metronidazole 
and tetracycline were more effective than placebo for papulopustular 
lesions.1 A subsequent systematic review found that anti-inflammatory 
doses of oral doxycycline (20–40 mg daily) were effective.3,4
Evidence for other oral drugs is limited or inconclusive
Limited supporting evidence exists for oral macrolides, isotretinoin, 
and spironolactone.1,2 Three small placebo-controlled RCTs found 
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insignificant or inconclusive benefits for ampicillin, 
oral clarithromycin plus omeprazole, and oral 
rilmenidine (a centrally acting, sympatholytic 
antihypertensive.)1
Many studies, little difference in drug effects
A large number of studies have compared the 
effectiveness of one treatment against another, but only 
one comparison demonstrated a statistically significant 
benefit. Two RCTs enrolling 104 patients found that 
oral doxycycline (40 mg daily) in combination with 
topical metronidazole reduced the number of lesions 
more than topical metronidazole alone (4 and 7 fewer 
lesions; P<.01 for both studies). It is unclear whether 
the reduction is clinically significant.3,5
 Not all therapies were equally well tolerated, 
however. Topical metronidazole produced fewer 
adverse events than topical azelaic acid (OR 4.56; 95% 
CI, 2.07–10.03).1 Doxycycline dosed at 40 mg daily 
produced fewer gastrointestinal adverse effects than 
100 mg daily (5% vs 26%; P value not given).4
Therapy for erythema and telangiectasia
A systematic review described multiple small case 
series that reported improvements in erythema and 
telangiectasias with pulsed-light therapy (188 cases) 
and laser therapy (82 cases).2 Another case series 
with 17 patients reported improvements with 
photodynamic therapy with red light.6
General skin care measures
A case series reported improved symptom scores 
among 20 patients using twice-daily metronidazole 
gel when they added moisturizing lotion to one side 
of their face.7 Expert opinion recommends using 
sunscreen and protective emollients and avoiding 
triggers that cause flushing, such as certain foods, 
beverages, and cosmetics.1,2
Recommendations
The American Acne and Rosacea Society guidelines 
state that good evidence supports 3 topical 
treatments—metronidazole, azelaic acid, and 
sulfacetamide/sulfur—as well as anti-inflammatory 
doses of oral doxycycline.
 The guidelines also list other topical and oral 
antibiotic treatments, but cite low-quality evidence 
for their efficacy and concerns about the emergence 
of antibiotic resistance. They advise appropriate skin 
care, including gentle cleansers, moisturizers, and sun 
protection.8
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Papulopustular acne rosacea: Doctors assess treatment  
efficacy in placebo-controlled trials1,2
Primary Number  Number Physician assessment 
intervention of trials of patients  of improvement vs placebo
Topical  9 488 OR 7.01 
metronidazole    (95% CI, 2.5–20)
Topical  4 778 OR 2.23 
azelaic acid   (95% CI, 1.66–3.00)
Topical  1 58 OR 3.17 
benzoyl peroxide   (95% CI, 1.08–9.31)
Topical sodium  1 94 90%–98% vs 
sulfacetamide    58%–68% 
with sulfur   improved (P<.01)
Oral doxycycline 2 577 9.5 and 11.8 fewer lesions  
   with doxycycline vs 4.3 and  
   5.9 fewer lesions with placebo  
   (P<.001 for both RCTs)
Oral tetracycline 3 152 OR 6.06  
   (95% CI, 2.96–12.4)
Oral metronidazole 1 27 OR 13.75  
   (95% CI, 2.05–92.04) 
CI, confidence interval; OR, odds ratio; RCTs, randomized controlled trials.
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Dear EBP Readers,
Have you ever wondered how long it takes for a new medical discovery 
to become widely accepted?
Researchers at the School of Medicine of the University of Ioannina 
decided to look into that very question.1 They used as a proxy for 
"widely accepted" the point when a study about an intervention 
received >1,000 citations. They then looked backward and sought 
the first mention of that intervention. It turns out that about 16 years 
pass between an effective intervention’s debut in the literature and the 
time it becomes "widely accepted."
Now 16 years is rather long. Sixteen years is long enough to go to 
college, medical school, residency, and spend a few years in practice. 
Sixteen years is also long enough for someone to stop exercising, 
develop insulin resistance, then frank diabetes, followed by kidney 
damage.
One might therefore argue that 16 years is just a bit slow on the uptake. 
Sixteen years means that new wonders coming out now will not be 
widely accepted until after I've retired. It is also likely that those same 
new wonders will not be widely accepted until after patients who might 
benefit have developed irreparable injuries.
But there are some interesting details beneath these statistics. Two 
drugs made it through the research gauntlet in only 4 years – indinavir 
and abciximab. Both drugs had strong financial backing from the 
developers, strong interest in research circles, and strong advocacy in 
the community. Clearly, concerted determination makes a difference.
Conversely, the researchers noted that out of 100 very promising claims 
of new discoveries between 1979 and 1983, only 5 were eventually 
licensed for clinical use and only 1 went on to extensive clinical use. 
Perhaps more sobering, nearly half of all studies that received >1,000 
citations were for therapies that were partially or fully refuted within a 
couple of years.
So this just raises another prickly question. How can we pick up the 
pace of translational processing without letting even more junk research 
through the gauntlet? Feel free to call me when you have the answer.
Regards,
Jon O. Neher, MD
 
 1.  Contopoulos-Ioannidis DG, Alexiou GA, Gouvais TC, Ioannidis JPA. Life cycle of transla-
tional research for medical interventions. Science. 2008; 321(5894):1298–1299.
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Prostate cancer: To screen or not?
Djulbegovic M, Beyth RJ, Neuberger MM, et al. Screening for prostate cancer: 
systematic review and meta-analysis of randomised controlled trials. BMJ. 2010; 
341:c4543.
This was a meta-analysis of 6 RCTs that compared a 
policy of screening for prostate cancer with prostate-
specific antigen (PSA) with or without digital rectal 
examination versus a policy of not screening. 
 Results showed no significant effect of screening 
on all-cause mortality or death from prostate cancer 
(RR=0.88; 95% CI, 0.71–1.09; P=.25). Screening 
did increase the probability of being diagnosed with 
prostate cancer (RR=1.46; 95% CI, 1.21–1.77; 
P<.001).
Bottom line: This review would not encourage us 
to start PSA screening, but does it provide sufficient 
evidence to stop it altogether? We think rather that 
it modifies the information we provide as we counsel 
men about this screening test. 
 First, there was a decrease in death from prostate 
cancer in patients who were screened, although the 
decrease did not achieve statistical significance; it 
is still possible that future RCTs will demonstrate 
decreased mortality. Second, while the meta-analysis 
itself was well done, the included RCTs were of 
moderate to low quality. Finally, no quality-of-life 
measures were included. 
 Based on the results of this study, we would 
inform patients that currently, the best evidence shows 
that screening with PSA does not reduce the risk of 
dying from prostate cancer.
Article Reviewer: Sue Slatkoff, MD
Summary Author: Anne L. Mounsey, MD
PURLs Criteria 
Relevant: Is the topic relevant to family medicine?
Valid: Are the findings scientifically valid?
Change in practice: Would this change practice?
Medical care setting: Is this implementable in clinic, etc?
Implementable: Can we implement this immediately?
Clinically meaningful: Are results clinically meaningful? 
Relevant Yes
Valid Yes
Change in practice Yes
Medical care setting   Yes
Implementable   Yes
Clinically meaningful   Yes
Comorbidities should guide conversations 
about prostate cancer screening
Crawford ED, Grubb R 3rd, Black A, et al. Comorbidity and mortality results from a 
randomized prostate cancer screening trial. J Clin Oncol. 2010 Nov 1. 
This RCT enrolled 76,639 men aged 55–74 years 
to compare the mortality impact of annual prostate 
cancer screening with prostate-specific antigen (PSA) 
and digital rectal exam (annually screened group) 
versus a usual-care group. A subgroup analysis was 
also conducted of men with comorbidities (including 
hypertension, diabetes, stroke, COPD, or BMI  
>30 kg/m2) and without comorbidities (healthy men). 
Men randomized to usual care received a wide range 
of PSA testing and examination; 52% received at least 
1 PSA during the study.
 Healthy men in the annually screened group 
experienced lower prostate cancer-specific mortality 
than healthy men in the usual-care group (adjusted 
hazard ratio [AHR] 0.56; 95% CI, 0.33–0.95; P=.03) 
after an average of 10 years of follow-up.
 Deaths from prostate cancer were infrequent 
in both groups, occurring in 0.22% (164/73,378) 
of all patients. The absolute risk reduction for men 
without comorbidities who received yearly screening 
versus usual care was 0.11% (0.29% vs 0.18%). The 
number needed to screen (NNS) to prevent 1 death 
from prostate cancer was therefore 909.
Bottom line: To our knowledge, this is the first 
convincing evidence that a subgroup of men may 
experience decreased mortality from prostate cancer 
screening. However, all-cause mortality rates were 
similar in both groups, regardless of comorbidities. 
 This study does not address the downsides of 
screening, such as unnecessary biopsies, unnecessary 
treatments for prostate cancer, or side effects of 
treatment such as incontinence and impotence. Such 
potential unintended consequences and the presence 
of comorbidities should be taken into account when 
advising men about annual prostate cancer screening.
Article Reviewer: Kohar Jones, MD
Summary Author: Kate Rowland, MD
Relevant Yes
Valid Yes
Change in practice Yes
Medical care setting   Yes
Implementable   Yes
Clinically meaningful   Yes
EBP
Evidence-Based Practice / Vol. 14, No. 7 5
EBM on the Wards
Blood pressure management after acute ischemic stroke
Bottom line
Current consensus guidelines recommend that if 
a patient is not eligible for thrombolytic therapy, 
blood pressure (BP) should not be treated until it is 
>220/120 mmHg. If the patient is otherwise eligible to 
receive thrombolytic therapy, the maximum permitted 
BP is 185/110 mmHg, because of an increased risk of 
hemorrhage above this value. Some evidence suggests 
that actively lowering BP within 36 hours of acute 
stroke does not worsen outcomes and decreases all-
cause mortality at 3 months.
Review of the evidence
A 2008 Cochrane review of 12 RCTs involving 1,153 
patients evaluated the effect of BP management regimens 
after an acute CVA.1 Eleven trials lowered BP with 
various agents, including calcium channel blockers, 
ACE inhibitors, angiotensin II receptor inhibitors, 
thiaizide diuretics, clonidine, or a combination thereof. 
The authors concluded that evidence is insufficient 
to suggest that altering BP immediately after a stroke 
alters outcome. Data seem to suggest that very high or 
very low BPs may be harmful. 
 A 2009 randomized, double-blind, placebo-
controlled trial assessed the efficacy and safety of early 
BP reduction (within 36 h) in 126 adult patients with 
an acute cerebral infarction.2 Patients were randomized 
to receive labetalol 50 mg PO (or IV in patients with 
dysphagia), lisinopril 5 mg PO (sublingual in patients 
with dysphagia), or matching placebo if hypertensive 
(defined as systolic BP >160 mmHg) and to treat to 
a goal of systolic BP 145–155 mmHg or a 15-mmHg 
reduction. The treatment was repeated at 4 and 8 hours 
if not at goal and then continued for up to 14 days. 
 The primary outcome was death or dependency 
at 2 weeks (dependency defined as a modified Rankin 
scale [mRS] score of >3 points), which occurred in 61% 
in the combined active treatment group versus 59% 
in the placebo group (RR=1.03; 95% CI, 0.80–1.3; 
P=.82). No difference was noted in early neurological 
deterioration (<72 h) in the active group (6%) compared 
with the placebo group (5%) (RR=1.2; 95% CI, 0.32–
4.5; P=.76). There was no increase in serious adverse 
events reported with active BP treatment compared 
with placebo (RR=0.91; 95% CI, 0.69–1.1; P=.50). 
However, all-cause mortality at 3 months was cut in 
half in the active treatment group (9.7% vs 20%; HR 
0.40; 95% CI, 0.2–1.0, P=.05).
Recommendation
A 2007 evidence-based guideline from the American 
Heart Association/American Stroke Association (AHA/
ASA) states if the arterial BP needs to be lowered, a 
reasonable goal would be to lower the pressure by 
approximately 15% during the first 24 hours, but 
that the exact BP that would mandate lowering after 
ischemic stroke is unknown.3 
 Expert consensus opinion holds that medications 
should be withheld unless systolic BP is >220 mmHg or 
diastolic BP is >120 mmHg, as long as there are no signs of 
end-organ involvement (TABLE).4 If the patient is eligible 
to receive thrombolytic therapy, goal BP is <185 mmHg 
systolic and <110 mmHg diastolic prior to treatment and 
<180 mmHg systolic and <105 mmHg diastolic during 
and after thrombolytic administration.
Maggie Ngar, DO
Corey Lyon, DO
Research FMR
Kansas City, MO
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Guidelines for management of BP  
after acute ischemic stroke4
Not eligible   
for thrombolytic therapy Treatment
Systolic <220 mmHg or  • Observe, unless signs of end-organ 
diastolic <120 mmHg  involvement, ie, aortic dissection,  
  acute myocardial infarction,  
  pulmonary edema, hypertensive 
  encephalopathy
Systolic >220 mmHg or  • Aim to reduce BP by 10%–15% 
diastolic >120 mmHg • Treat with IV antihypertensives,  
  nitroprusside, labetalol, or nicardipine
Eligible for thrombolytic therapy 
Pretreatment • Observe 
Systolic <185 mmHg or   
diastolic <110 mmHg 
Posttreatment • Treat with IV antihypertensives,  
Systolic >180 mmHg or   nitroprusside, labetalol, or 
nicardipine 
diastolic >105 mmHg 
TABLE
EBP
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What is the prognostic implication of right 
bundle branch block in asymptomatic coronary 
artery disease patients?
Evidence-Based Answer
In patients with asymptomatic coronary artery disease 
(CAD), complete right bundle branch block (RBBB) 
likely increases mortality risk compared with similar 
patients without complete RBBB. (SOR: B, based on 3 
cohort studies with heterogeneous results.) Incomplete 
RBBB in patients with CAD does not affect mortality 
risk. (SOR: B, based on 1 cohort study.)
In 1 prospective cohort study, 7,073 patients with 
known or suspected CAD were referred for exercise 
treadmill stress testing with thallium imaging. These 
patients were evaluated for the presence or absence of 
bundle branch block (BBB), and followed for a mean 
of 6.7±1.6 years. The primary endpoint was all-cause 
mortality. Patients were excluded if they had valvular 
or congenital heart disease, congestive heart failure, 
pre-excitation syndrome, or a pacemaker. The mean 
age of patients without RBBB was 60±11 years, and of 
those with RBBB was 66±9 years. One hundred ninety 
patients (3%) had complete RBBB and 305 (4%) had 
incomplete RBBB.1
 The overall mortality of patients without complete 
RBBB or left bundle branch block (LBBB) was 11%. For 
patients with incomplete RBBB, mortality was 10%. 
Complete RBBB was associated with a 24% mortality 
rate (HR 1.5; 95% CI, 1.1–2.1; P=.007), and was as 
strong a predictor of mortality as complete LBBB (24% 
mortality; HR 1.5; 95% CI, 1.1–2.0; P=.017).1
 Another cohort study of 15,609 patients with 
known CAD undergoing coronary and left ventricular 
angiography identified 272 (1.7%) with RBBB. The aim 
of this study was to determine if BBB was an independent 
risk factor for mortality. Exclusion criteria included 
valvular heart disease, nonischemic cardiomyopathy, 
or congenital heart disease, and the average age of all 
patients was 54±9 years. Those who qualified were 
followed for a mean of 4.9±1.3 years, with the endpoint 
being all-cause mortality.2
 The presence of RBBB in a patient with known 
CAD increased the mortality rate above that of patients 
with CAD but without BBB (26% vs 15%, respectively; 
P<.0001). Unlike the aforementioned cohort study, 
the mortality increase with LBBB was larger than 
that associated with complete RBBB (58% vs 26%; 
P<.0001).2
 In a third prospective cohort study, 9,541 patients 
who had known asymptomatic CAD were evaluated 
for the presence or absence of BBB, then followed for 
a median of 4.5 years. The primary endpoint of the 
study was major cardiovascular events, but patients 
were also evaluated for all-cause mortality. Exclusion 
criteria included heart failure or known left ventricular 
dysfunction, uncontrolled hypertension, significant 
valvular disease, renal disease, and major noncardiac 
illness. The mean age of patients was 65.9±7 years, for 
both those with and without RBBB.3
 Mortality rates were higher in patients with RBBB 
versus those without, but unlike the other 2 studies, 
the difference was small and not statistically significant 
(13.8% vs 11.1%; 95% CI, 0.80–1.35).3
Kaitlin Varady, MD
Richard Guthmann, MD, MPH
Advocate Illinois Masonic FMR
Chicago, IL
 1.  Hesse B, Diaz L, Snader C, Blackstone EH, Lauer MS. Complete bundle branch block 
as an independent predictor of all-cause mortality: report of 7,073 patients referred for 
nuclear exercise testing. Am J Med. 2001; 110(4):253–259. [LOE 1b]
 2.  Freedman RA, Alderman E, Sheffield LT, Saporito M, Fisher LD. Bundle branch block 
in patients with chronic coronary artery disease: angiographic correlates and prognostic 
significance. J Am Coll Cardiol. 1987; 10(1):73–80. [LOE 1b]
 3.  Sumner G, Salehian O, Yi Q, et al. The prognostic significance of bundle branch block in 
high-risk chronic stable vascular disease patients: a report from the HOPE trial. J Cardio-
vasc Electrophysiol. 2009; 20(7):781–787. [LOE 1b]
GLOSSARY
ARR=absolute risk reduction
CDC=Centers for Disease Control and Prevention
CI=confidence interval
CT=computed tomography
FDA=US Food and Drug Administration
HR=hazard ratio
LOE=level of evidence
MRI=magnetic resonance imaging
NNH=number needed to harm
NNT=number needed to treat
OR=odds ratio
RCT=randomized controlled trial
RR=relative risk
SOR=strength of recommendation
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What cold sore medication is most effective  
at speeding resolution?
Evidence-Based Answer
Of the oral antiviral medications, famciclovir showed the 
quickest time to healing (2 days sooner than placebo). 
Among topical treatments available in the United 
States, zinc oxide cream showed the quickest time to 
healing (1.5 days sooner than placebo), although the 
studies for 1% penciclovir cream and 10% docosanol 
cream (each 0.7 days sooner than placebo) are of higher 
quality. (SOR: B, based on a comparison of placebo-
controlled trials.)
A cold sore (herpes labialis) is a self-limiting, painful, 
blistering lip and perioral rash typically caused by 
herpes simplex virus type 1. Healing occurs in 7 to 10 
days without treatment.1 Multiple potential treatments 
(oral and topical) for shortening duration of lesions and 
symptoms have been studied, and the TABLE provides 
a brief summary of trial results.2–5 Not included in the 
Table was one article discussing 4 case reports of topical 
herbal preparations (not FDA approved), each of which 
had reported healing times of 3 to 4 days.6
Margot Savoy, MD, MPH, FAAFP, CPE
Christiana Care FMRP
Wilmington, DE
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 6.  Hijikata Y, Tsukamoto Y. Effect of herbal therapy on herpes labialis and herpes genitalis. 
Biotherapy. 1998; 11(4):235–240. [LOE 4]
Healing time for recurrent herpes labialis by treatment
 Participants  Mean difference from placebo  
Medication (Adults) Dosing (significance)
Oral antiviral agents
Acyclovir2 673 400 mg 5×/d × 5 days –0.6 day (P=.007)
Famciclovir2 701 500 mg × 1 dose –2.1 daysa (P=.01) 
 
  500 mg BID × 1 day –2.5 daysa (P=.01)
Valacyclovir2 954 participants 2 g BID × 1 day –1 day (P<.001) 
 aged >12 y   
  
 603 2 g BID × 1 day –1.3 days 
   (95% CI, –1.9 to –0.7) 
  
 902 2 g BID × 1 day then  –0.5 day (P<.001) 
  1 g BID × 1 day 
Topical agents
1% Penciclovir cream2 2,209 Every 2 h when awake × 4 days –0.7 day (P<.001)
Acyclovir 5%2 689 5×/d × 4 days –0.5 day 
   (HR 1.23; 95% CI, 1.06–1.44)
Acyclovir 5% + hydrocortisone 1%3 833 5×/d × 5 days –0.8 day (P=.008)
Zinc oxide2 (available over the counter) 46 2×/h during waking hours –1.5 days (P=.018)
1.8% Tetracaine cream2 (not available in U.S.) 72 6×/day –2.1 days (P=.002)b
1,5-Pentanediol gel4 (not FDA approved) 102 8×/d × 5 days –2 days (P<.001)c
Docosanol 10% cream5 (available over the counter) 737 5×/d –0.7 day 
   (95% CI, 0.08–0.92)
Adults= immunocompetent and aged >18 years; CI=confidence interval, HR=hazard ratio. 
aStudy only reported median number of days, not mean.
bOutcome measure for this study was scab loss. cOutcome used was a combined symptom score (pain, blistering, or swelling).
TABLE
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What is the best use of serum markers  
in the evaluation of threatened miscarriage?
Evidence-Based Answer
Ultrasound is the most definitive test to determine 
pregnancy location and viability. (SOR: C, based on 
expert opinion.) Serial human chorionic gonadotropin 
(hCG) levels are useful when ultrasound is nondiagnostic 
or initial hCG levels are less than 1,500–2,000 
IU/L; failure to attain at least a 53% increase in  
2 days indicates abnormal gestation. (SOR: B, based 
on a cohort study.) A low progesterone level can 
signify nonviability, but cannot locate a pregnancy. A 
combination of hCG and progesterone may be more 
useful than either serum marker alone. (SOR: B, based 
on a cohort study.)
Threatened abortion is defined as bleeding before 
20 weeks’ gestation, and occurs in around 20% of 
recognized pregnancies.1 Consensus guidelines from the 
American College of Obstetricians and Gynecologists 
(ACOG) recommend transvaginal ultrasonography 
for the evaluation of early pregnancy pathology, 
including bleeding. When diagnostic, ultrasound can 
locate pregnancy as definitely intra- or extrauterine. If 
ultrasound is equivocal, ACOG guidelines suggest the 
use of serum markers to aid in diagnosis.2
 In a retrospective cohort study of 287 women 
who presented to an emergency department with 
first trimester bleeding, researchers followed serial 
serum hCG measurements until definitive ultrasound 
diagnosis of intrauterine pregnancy. Ninety-nine 
percent of viable singleton pregnancies between 4 and 
10 weeks’ gestation had at least a 53% increase in hCG 
over 2 days. Pregnancies not attaining this increase in 
hCG could be more reliably diagnosed as abnormal. 
This study did not address the hCG patterns of ectopic 
pregnancies.3
 A systematic review of 18 cohort studies 
(6,801 patients) examined the usefulness of a single 
progesterone level for the diagnosis of ectopic pregnancy 
in patients between 4 and 20 weeks’ gestation. Included 
studies had significant heterogeneity and different 
progesterone thresholds, preventing calculation of 
summary sensitivity or specificity.4
 In a subset of studies reporting cutoff at 5 ng/mL, 
only 5 of 1,615 (0.3%) patients with viable pregnancy 
had levels <5 ng/mL. However, progesterone could not 
differentiate ectopic from intrauterine location. There is 
no evidence to support serial progesterone measurement.4
 A single-site retrospective cohort study of 245 
women with naturally conceived pregnancies measured 
serum hCG and progesterone levels between 4 and 
5 weeks’ gestation. A total of 175 women who presented 
with threatened abortion (108 with ongoing pregnancies 
and 67 with eventual abortions) were compared with 
70 controls without bleeding.1
 Using a receiver operating characteristic curve, 
researchers found the combination of hCG and pro-
gesterone (cutoff values 7,236 mIU/mL and 16 ng/mL, 
respectively) had 88% sensitivity and 84% specificity 
for a continuing pregnancy (positive likelihood ratio 
[LR+] 5.6; negative likelihood ratio [LR–] 0.14). Serum 
hCG alone had 64% sensitivity and 81% specificity 
(LR+ 3.5; LR– 0.44) and progesterone alone had 76% 
sensitivity and 70% specificity (LR+ 2.57; LR– 0.34).1 
These cutoff values have not been validated in a pro-
spective trial.
Laura Morris, MD
James J. Stevermer, MD, MSPH
U of MO
Columbia, MO
 1.  Duan L, Yan D, Zeng W, Yang X, Wei Q. Predictive power progesterone combined with beta 
human chorionic gonadotropin measurements in the outcome of threatened miscarriage. 
Arch Gynecol Obstet. 2011; 283(3):431–435. [LOE 2b]
 2.  American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 94: 
Medical management of ectopic pregnancy. Obstet Gynecol. 2008; 111(6):1479–1485. 
[LOE 5]
 3.  Barnhart KT, Sammel MD, Rinaudo PF, Zhou L, Hummel AC, Guo W. Symptomatic pa-
tients with an early viable intrauterine pregnancy: hCG curves redefined. Obstet Gynecol. 
2004; 104(1):50–55. [LOE 2b]
 4.  Mol BW, Lijmer JG, Ankum WM, van der Veen F, Bossuyt PM. The accuracy of a single 
serum progesterone measurement in the diagnosis of ectopic pregnancy: a meta-analysis. 
Human Reprod. 1998; 13(11):3220–3227. [LOE 2a]
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In evaluating hyponatremia in a patient who  
is taking a diuretic, is there any value  
to checking uric acid level?
Evidence-Based Answer
Measuring uric acid (either as a simple serum level 
or as a fractional excretion) may be beneficial in 
evaluating hyponatremia in patients taking diuretics 
because it helps differentiate between the syndrome 
of inappropriate antidiuresis (SIAD) and extracellular 
volume depletion. (SOR: B, based on diagnostic cohort 
studies.)
Correctly identifying the cause of hyponatremia in 
a patient taking a diuretic is difficult because the 
enhanced sodium excretion alters results of the clinical 
tests usually used for evaluation. Serum uric acid 
(S-UA) concentration and the fractional excretion of 
uric acid (FE-UA) have been proposed as alternative 
tests to evaluate hyponatremia in these patients.
 One cohort study evaluated 57 hyponatremic 
patients using diuretics. Eligible patients (aged 
>18 years) had serum sodium <130 mmol/L and serum 
osmolality <280 mOsm/L on hospital admission. 
Utilizing a standardized method to assess volume status, 
which included careful measurement of orthostatic 
changes in heart rate and blood pressure, 15 patients 
were classified as having SIAD and 42 as non-SIAD.1 
 FE-UA was more accurate than urinary sodium, 
fractional excretion of sodium, fractional excretion of 
urea, and S-UA in differentiating SIAD versus non-SIAD. 
A normal FE-UA is approximately 10%. A FE-UA >12% 
was 100% specific for SIAD (ruling in the syndrome), 
while FE-UA <8% excluded SIAD (sensitivity=86%). 
The study authors identified limitations of using 
FE-UA for patients with cirrhosis, cerebral salt wasting 
syndrome, or those taking uricosuric medications, all 
of which produce an elevated FE-UA.1 (Sensitivity and 
specificity for S-UA derived from this study are shown 
in the TABLE.)
 Another inpatient-based prospective study 
examined S-UA values in 40 adult patients with 
hyponatremia who were taking diuretics. The cause of 
hyponatremia was determined after a detailed history, 
physical examination, and review of laboratory data.2
 Compared with other biochemical markers, S-UA 
values of 4 mg/dL effectively discriminated between 
SIAD and extracellular volume depletion states with 
a sensitivity of 90% and a specificity of 75% (TABLE). 
The receiver operating characteristic curve showed 
a discriminative value for S-UA to be 0.865. S-UA 
levels <4 mg/dL were consistent with SIAD, whereas 
S-UA levels ≥4 mg/dL indicated extracellular volume 
depletion.2
Janelle Maxwell, DO
Denver Health Medical Center
Denver, CO
Bradford T. Winslow, MD
Swedish FMR
Littleton, CO
Mary Onysko, PharmD, BCPS
University of WY School of Pharmacy
Laramie, WY
 1.  Fenske W, Störk S, Koschker AC, et al. Value of fractional uric acid excretion in differ-
ential diagnosis of hyponatremic patients on diuretics. J Clin Endocrinol Metab. 2008; 
93(8):2991–2997. [LOE 2b]
 2.  Liamis G, Christidis D, Alexandridis G, Bairaktari E, Madias NE, Elisaf M. Uric acid ho-
meostasis in the evaluation of diuretic-induced hyponatremia. J Investig Med. 2007; 
55(1):36–44. [LOE 2b]
Serum uric acid for predicting SIAD  
in patients taking a diuretic (cutoff 4 mg/dL)
TABLE
Study Sensitivity (%) Specificity (%)  LR+ LR–
 #1 65 76 2.7 0.46
 #2 90 75 3.6 0.13
LR+=positive likelihood ratio; LR–=negative likelihood ratio; SIAD=syndrome of 
inappropriate antidiuresis.
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What is the best screening test  
for past tuberculosis infection?
Evidence-Based Answer
Interferon-γ release assays (IGRAs) are at least as 
sensitive as and more specific than the tubercu-
lin skin test (TST) in diagnosing latent Mycobacte-
rium tuberculosis infection (LTBI). When screening 
for LTBI, it is acceptable to use an IGRA in the place 
of TST. (SOR: A, based on consistent findings from  
2 systematic reviews.) In patients with Bacillus 
Calmette-Guérin (BCG) vaccination, an IGRA is pre-
ferred over the TST. (SOR: A, based on consistent find-
ings from 2 systematic reviews.)
The 2 most commonly used IGRA tests are the 
QuantiFERON-TB Gold In-Tube test (QFT-GIT) 
and T-Spot.TB test (T-Spot). An inherent challenge 
of screening for LTBI is the lack of a gold standard 
to confirm latent infection; in most studies a clinical 
diagnosis of an active TB infection is used as a surrogate 
standard.
 In 2010, the Centers for Disease Control (CDC) 
performed a systematic review of 96 studies comparing 
sensitivity, specificity, and agreement between TST 
and IGRAs.1 The pooled results are shown in TABLE 1. 
The sensitivity was highest for T-Spot at 90% and 
the specificity was highest for the QFT-GIT at 99%. 
Limitations to this review included variable TST cutoffs 
and small sample sizes in the T-Spot studies.
 Another systematic review, from 2008, included 
38 studies looking at sensitivity and specificity of 
IGRAs and TST (TABLE 2).2 This study had similar 
limitations as the CDC systematic review. The highest 
pooled sensitivity was seen in the T-Spot at 90% 
(95% CI, 86–93). The sensitivities 
of the QFT-GIT and TST were 
roughly equivalent. Specificity was 
highest with QFT-GIT at 98% 
(95% CI, 96–99). With regard 
to BCG-vaccinated populations, 
QFT-GIT had a much higher 
specificity at 96% compared with 
TST at 59% (which varied from 
35% to 79% across studies).
 A prospective study looked at 
the agreement between different 
IGRAs and the sensitivity of TST.3 
This was the only study to use positive QFT-GIT and 
T-Spot concordance to define cases of LTBI. Using 
this definition, the sensitivity for TST was 71.5% at a 
10-mm cutoff and 31.3% with a 15-mm cutoff (with 
total cohort TST specificity 64.5%).
 The CDC recommends using either TST or IGRA 
in combination with risk assessment. IGRA testing is 
preferable to TST if a patient is not likely to complete the 
TST or if a person has received BCG. TST is preferred 
in children <5 years.
Juliann Gaydos-Gabriel, MD
Elizabeth Hutchinson, MD
Swedish Medical Center FMR
Seattle, WA
 1.  Mazurek GH, Jereb J, Vernon A, et al; for the Centers for Disease Control and Prevention. 
Updated guidelines for using interferon gamma release assays to detect Mycobacterium 
tuberculosis infection—United States, 2010. MMWR Recomm Rep. 2010; 59(RR-5):1–
25. http://www.cdc.gov/mmwr/pdf/rr/rr5905.pdf. Accessed June 13, 2011. [LOE 1a]
 2.  Pai M, Swerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis 
of latent tuberculosis infection: an update. Ann Intern Med. 2008; 149(3):177–184. 
[LOE 1a]
 3.  Diel R, Loddenkemper R, Meywald-Walter K, Gottschalk R, Nienhaus A. Comparative 
performance of tuberculin skin test, QuantiFERON-TB-Gold In Tube assay, and T-Spot.
TB test in contact investigations for tuberculosis. Chest. 2009; 135(4):1010–1018. 
[LOE 1b]
CDC systematic review results  
comparing TB tests1
TABLE 1
Test Sensitivity Specificity
QuantiFeron-TB-Gold In Tube assay 83% 99%
T-Spot.TB assay 90% 88% 
  (limited data) 
Tuberculin skin test 89% 85%
Annals of Internal Medicine systematic review  
results comparing TB tests2
TABLE 2
   Specificity among  Specificity among 
   BCG-vaccinated non-BCG-vaccinated 
Test Sensitivity Specificity participants participants
QuantiFeron-TB-Gold  70% 98% 96% 99% 
In Tube assay
T-Spot.TB assay 90% 93% N/A N/A
Tuberculin skin test 77% N/A 59% 97%
N/A=not available.
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What is the etiology and significance  
of otherwise asymptomatic temporomandibular 
(TMJ) joint popping and clicking?
Evidence-Based Answer
The etiology is unknown. Asymptomatic TMJ noises 
tend to have a waxing and waning course and do not 
need evaluation or treatment. (SOR: C, based on expert 
opinion.)
TMJ noises are common in the general population. 
Various authors estimate that audible sounds occur in 
17% to 40% of adult patients (up to 80% if auscultated 
with a stethoscope) and nonpainful clicking occurs 
in 16% to 65%.1,2 In adolescents, audible popping 
occurs in 1% to 5% and clicking is present in 5% to 
34%.3 Many authors consider the nonpainful clicking 
and popping to be a normal variant.1 Crepitus or 
loud cracking with popping sounds are thought to be 
clinically more significant and occur in 10% to 24% of 
the adult population.4
 The sources of TMJ noise have been hypothesized 
to include poor chewing coordination, articular 
cartilage dislocation, irregular articular surfaces, and 
prior injury; however, none has been shown to be the 
definitive cause.1 
 The natural history of the syndrome was 
investigated in an observational study of 402 randomly 
selected patients, aged 7, 11, and 15 years old, who were 
interviewed at baseline and re-interviewed 5, 10, and 
20 years later (80% of the initial 402 were followed 
through the whole study). Symptoms appeared to come 
and go with time, with 55% reporting TMJ sounds at 
baseline, but only 5% of patients reporting sounds at 
all 4 evaluations.5
 Other studies have investigated progression of TMJ 
associated with intervention. A retrospective chart review 
identified 190 patients from a university TMJ clinic and 
several private practices with a chief complaint of jaw 
clicking. A variety of treatments had been prescribed, 
including relaxation, physical therapy, and TENS 
(transcutaneous electrical nerve stimulation) unit therapy. 
The patients were contacted by phone 3 to 15 years later 
to assess resolution or progression of symptoms. Of 
the university clinic patients, 73% had a resolution of 
symptoms and 26% were unchanged (1% worsened); of 
the private patients, 51% had a resolution of symptoms 
and 45% were unchanged (4% worsened).6 
 A separate study followed 94 patients who presented 
to a TMJ clinic. At initial assessment all patients were 
taught jaw-opening exercises. No other interventions 
were provided; a follow-up was conducted 1 to 10 years 
after the initial appointment to assess if clicking had 
resolved or progressed to pain. Over a 10-year period, 
70% of patients eventually progressed to pain with the 
clicking, at a rate of approximately 6% per year. Eleven 
percent had persistent clicking without pain and in 
19% the clicking resolved.7
 Most authors agree that treatment is not necessary 
for isolated popping and clicking of the jaw.1–3
Capt Brian Davis, MD
David Grant Medical Center
Travis AFB, CA
Justin Bailey, MD, FAAFP
FMR of Idaho
Boise, ID
The opinions and assertions contained herein are the private views 
of the author and are not to be construed as official or as reflecting the views 
of the Medical Department of the U.S. Air Force or the U.S. Air Force at large.
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 2.  Gross A, Gale EN. A prevalence study of the clinical signs associated with mandibular 
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 3.  Barbosa Tde S, Miyakoda LS, Pocztaruk Rde L, Rocha CP, Gavião MB. Temporal man-
dibular disorders and bruxism in childhood and adolescence: review of the literature. Int 
J Pediatr Otorhinolaryngol. 2008; 72(3):299–314. [LOE 3a]
 4.  Rinchuse DJ, Abraham J, Medwid L, Mortimer R. TMJ sounds: are they a common finding 
or are they indicative of pathosis/dysfunction? Am J Orthod Dentofacial Orthop. 1990; 
98(6):512–515. [LOE 3a]
 5.  Egermark I, Carlsson GE, Magnusson T. A 20-year longitudinal study of subjective symp-
toms of temporomandibular disorders from childhood to adulthood. Acta Odontol Scand. 
2001; 59(1):40–48. [LOE 1b]
 6.  Greene CS, Laskin DM. Long-term status of TMJ clicking in patients with myofascial pain 
and dysfunction. J Am Dent Assoc. 1988; 117(3):461–465. [LOE 2b]
 7.  Laskin DM, Greene CS. Influence of the doctor-patient relationship on placebo therapy 
for patients with myofascial pain-dysfunction (MPD) syndrome. J Am Dent Assoc. 1972; 
85(4):892–894. [LOE 1b]
“Evidence based medicine is the conscientious, 
explicit, and judicious use of current best evidence  
in making decisions about the care of individual 
patients. The practice of evidence based medicine 
means integrating individual clinical expertise with 
the best available exter nal clinical evidence from 
systematic research.” 
— Sackett DL et al. Evidence based medicine:  
what it is and what it isn’t. BMJ 1996; 312:71–72.
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Behavioral Health Matters 
Is acupuncture an effective treatment for generalized anxiety disorder?
Summary
Some evidence suggests acupuncture may be beneficial 
in the treatment of generalized anxiety disorder (GAD), 
but there is insufficient high-quality data to demonstrate 
its efficacy over placebo or standard pharmacologic 
management.
The evidence
GAD is the most common anxiety disorder encountered 
in primary care, affecting between 5.3% and 7.6% of 
patients, and almost half of patients with GAD are first 
diagnosed by a primary care physician.1 
 A systematic review of acupuncture for anxiety 
examined 12 studies: 4 RCTs and 2 nonrandomized 
controlled trials of patients with GAD or anxiety 
neurosis, and 6 studies of patients with situational 
anxiety.2 Of the studies on GAD or anxiety neurosis, 2 
found no difference between acupuncture and control 
groups, 3 favored acupuncture, and 1 showed benefits 
for acupuncture and behavioral therapy combined. 
 In 1 of the RCTs, 39 patients with GAD received 
either electroacupuncture 45 minutes a day or trazodone 
100 to 150 mg daily for 6 weeks. The Hamilton Anxiety 
Scale was given pre- and posttreatment, and scores 
<8 were defined as “cure,” while a score reduction of 
≥50% was defined as “marked effect.” No significant 
difference was noted between the groups. In the 
acupuncture group, 2 of 20 were cured and 11 attained 
a marked effect. In the control group, 1 of 19 was cured 
and 10 attained a marked effect.2
 Another RCT compared traditional 
semistandardized acupuncture methods, one of which 
included herbal remedies, with doxepin in 296 patients 
with anxiety neurosis. A treatment group received 
any 2 of 4 different acupuncture methods daily for 
30 sessions and a control group received doxepin 
25 mg PO 3 times daily. Symptomatic improvement (not 
clearly defined) was evident in 94.3% of the treatment 
group and 96.4% of the control group.2 
 In another RCT, 43 patients with minor depression 
and 13 patients with GAD were randomly assigned to 
receive 10 sessions of acupuncture or 10 sessions of 
sham acupuncture. In the acupuncture group 60.7% 
showed a treatment response (measured by Clinical 
Global Impression score), compared with 21.4% of 
the control group (P<.01). Among patients diagnosed 
with GAD, 6 of 7 subjects in the acupuncture group 
showed improvement, versus only 2 of 6 in the sham 
group.2
 A controlled clinical trial compared three 10-day 
sessions of acupuncture combined with flupentixol 
(a typical antipsychotic), melitracen (a tricyclic 
antidepressant), and oryzanol (rice bran oil) to therapy 
with this drug regimen alone for 100 patients with 
anxiety neurosis. More patients were cured in the 
combined group than the group that received drug 
therapy alone (96% vs 64%, respectively; P<.01). 
Duration of the trial was 2 months to 30 years. Cure 
was determined by subjective assessment by physicians, 
the process of which was not described.2
 In a large RCT, 240 patients with anxiety neurosis 
were randomly assigned to receive acupuncture, 
behavioral desensitization (BD), or a combination of 
acupuncture and BD. The patients received between 10 
and 40 treatment sessions. Clinical symptoms and Zung 
anxiety rating scale scores (possible scores between 20 
and 80) were administered pre- and posttreatment. 
“Cure” was defined as the absence of clinical symptoms 
and Zung scores <45. Cure was reported by 20% of the 
acupuncture-only group, 26.3% of the BD group, and 
52.5% of the combined therapy group. The combined 
therapy group had a significantly greater improvement 
rate than either treatment alone after a course of 10 
sessions (P<.01).2 The trial duration was 2 weeks to 
16 years.
 Most of the studies reviewed used problematic 
methodology or data analysis, or both. In the studies 
using drug therapy as controls, the drug regimens were 
not first-line for anxiety treatment and suboptimal 
dosing was used. Additionally, measures of clinical 
outcome were not consistent or well described and 
various methods of acupuncture were used.
Amanda J. Reeder, MS, MD
Vanessa Rollins, PhD
Rose FMR
Denver, CO
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Football-related injuries
The most popular sport in America based on 
participation numbers in high school. Participants are 
both male and female (at high school level), and the 
most common injuries they encounter are knee, ankle, 
and head injuries.
Factors affecting injury rates
	 •	Grass	versus	artificial	turf
  –  Injuries on grass are more common than on 
artificial turf
	 •	Footwear
  –  Length of cleats affects torsion forces on ankle, 
leading to knee and ankle injuries
	 •	Protective	equipment
  –  Helmet, mouth guard, shoulder pads, hip pads, 
knee pads all reduce risk of injury
Most common injuries
 1.  Knee injuries (internal derangement): Most 
common injury in games (18%) and practice 
(12%)
 2.  Foot and ankle injuries: Second most common 
football injury
 3.  Shoulder injuries: Account for 10% of football 
injuries
 4.  Exertional heat illness: Most common during 
preseason, accounting for 6% of preseason 
injuries
 5. Concussion rate: 0.72 per 100,000 athletes
Cervical spine injuries
Usually from tucking chin at impact. Encourage 
coaches to teach “heads up” tackling
MRSA in athletes
High MRSA transmission rates among players in 
practice and games
Author:  David Volk, DO, Naval Hospital JAX,  
Jacksonville, FL
Editor:  Carol Scott, MD, U of Nevada, Reno, NV
Anal fissure
A tear of the lining of the anal canal, distal to the 
dentate line, causing pain and bleeding. Chronic anal 
fissures are present more than 6 weeks; fibrosis at the 
base.
Incidence, prevalence
	 •	Difficult	to	establish
	 •		87.5%	of	patients	with	benign	anorectal	diseases	
do not consult a physician
	 •		During	a	1990s	German	study	in	unselected	
neurological patients, prevalence was 1.6% in 
males and 2.2% in females
Therapeutics
Acute treatment (SOR C):
	 •	Conservative	therapy	has	43%–87%	cure	rate
	 •		Fiber	supplementation	keeps	stools	formed	 
and soft
	 •		Sitz	baths	after	bowel	movements	relax	 
anal sphincter
	 •		Anesthetic	creams	no	more	helpful	than	sitz	baths	
and fiber
Medical therapies (SOR A):
	 •		Meta-analysis	showed	nitroglycerin	ointment	
significantly better than placebo (49% vs 37%), 
but recurrence about 50%
	 •		Botulism	toxin	injections,	diltiazem,	and	
nifedipine equal to nitroglycerin ointment, with 
fewer adverse effects
	 •		Major	adverse	effects:	headache	(nitroglycerin	and	
calcium channel blockers), flushing (nitroglycerin)
Prognosis
	 •	75%	heal	without	treatment	or	with	sitz	baths
Authors:  Nathan Carlson, MD, and Robert Theal, MD,  
Kaiser Permanete Medical Center FPRP,  
Riverside, CA
Editor:  Robert Marshall, MD, MPH, Capt MC USN,  
Puget Sound FMR, Naval Hospital, Bremerton, WA
To review complete topic monograph visit  
www.fpin.org/page/ebpemedref
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Spotlight on Pharmacy
How prevalent is fluoroquinolone resistance in gonorrhea?
Bottom line
Fluoroquinolone resistance among isolates of Neisseria 
gonorrhoeae is increasing. (SOR: C, based on multiple 
patient-oriented studies.) Surveillance studies are 
ongoing; as yet, no evidence of increased resistance has 
been found to cephalosporins or azithromycin.
Evidence summary
From 1993 through 2000, fluoroquinolones were the 
drug class of choice for treating Neisseria gonorrhoeae, 
the second most common sexually transmitted disease 
(STD) diagnosed in the United States, due to their high 
efficacy, availability, and convenience of single-dose 
therapy. However, in the last decade, resistance has 
become more prevalent in the United States and many 
parts of the world.1
Fluoroquinolone resistance increasing in Canada
A Canadian epidemiologic investigation using public 
health laboratory records exhibited fluoroquinolone 
resistance to gonorrhea increasing from 4% to 
28% between 2002 and 2006. Examination of 
fluoroquinolone-resistant isolates (n=695) and 
fluoroquinolone-sensitive (control) isolates (n=688) 
demonstrated more resistance in men (OR 3.1; 95% 
CI, 2.3–4.1) and those older than 30 years (OR 3.1; 
95% CI 2.4–3.8). This study found fluoroquinolone 
resistance in Ontario to be similar to the resistance 
reported in the West Coast of the United States.2
Resistance increasing in United States, too:  
Gonococcal Isolate Surveillance Project
Antibiotic resistance to gonorrhea is monitored in the 
United States by the Gonococcal Isolate Surveillance 
Project (GISP), a national surveillance system of STDs 
in 25 to 30 clinics, coordinated within 5 regional 
laboratories and the Centers for Disease Control 
and Prevention (CDC). From 1988 to 2003 the GISP 
collected 82,604 urethral gonococcal isolates from 
men (mean age 26 years; 74% black, 13% white, 11% 
Hispanic, 1% Asian, 1% American Indian). Among all 
patients studied, 42% were from the West Coast, 22% 
from the Midwest, 8% from the Northeast, and 29% 
from the South.2 
 From 1990 to 2003 the percentage of isolates 
resistant to ciprofloxacin increased from 0% to 4.1% 
(P<.001 for trend) and the presence of fluoroquinolone-
resistant isolates increased from 39% to 70% of cities, 
with Hawaii and California accounting for 75% of 
these resistant isolates. Isolates with resistance to 
ciprofloxacin have demonstrated resistance to other 
fluoroquinolones as well.3
 Generalizability of GISP data is debated, because 
it tests less than 2% of gonococcal infections reported 
in the United States, obtains all isolates from public 
clinics, and oversamples the West Coast (which is 
more proximal to Asia, where new resistant strains of 
N gonorrhoeae have often been first detected). In the 
GISP sample, resistance to cephalosporins, azithromycin, 
and spectinomycin was rare.3
Recommendation
The CDC currently recommends that fluoroquinolone 
antibiotics no longer be used as treatment for gonococcal 
infections, and that a cephalosporin be prescribed 
(ceftriaxone or cefixime).1,4
Cassandra Plummer, MD
Brice Labruzzo Mohundro, PharmD
Baton Rouge General FMRP
Baton Rouge, LA
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1  To become knowledgeable about evidence-based 
solutions to commonly encountered clinical problems
 2  To understand how ground-breaking research is changing 
the practice of family medicine
 3  To become conversant with balanced appraisals of drugs 
that are marketed to physicians and consumers.
Evidence-Based Practice learning objectives
EBP
1.  What is the role of progesterone measurement in the evaluation  
of threatened abortion?
	 o	 a. Progesterone level <5 ng/mL indicates an ectopic pregnancy
	 o	 b.  Increasing serial progesterone levels in the face of continued 
bleeding indicate viability
	 o	 c.  There is no role for progesterone in the evaluation  
of threatened abortion
	 o	 d.  Progesterone level <5 ng/mL indicates an abnormal,  
nonviable pregnancy
2.  Problems arise in trying to generalize data from the Gonococcal Isolate 
Surveillance Project because
	 o	 a.  Samples are obtained only in the southern  
United States
	 o	 b. No reference labs are used
	 o	 c. Only infections in women are included
	 o	 d. <2% of cases are sampled
3.  Patients with nonpainful temporal mandibular joint sounds  
may be reassured that this condition:
	 o	 a. Has a well-defined cause
	 o	 b. Never progresses to joint dysfunction
	 o	 c. Is present in up to 90% of the adult population
	 o	 d. May go away on its own
4.  Which oral antiviral medication has been shown to improve healing  
of herpes labialis lesions the fastest?
	 o	 a.  Acyclovir
	 o	 b. Famciclovir
	 o	 c. Valacyclovir
	 o	 d. None of the above
5. The QuantiFeron tuberculosis (TB) assay
	 o	 a.  Differentiates latent from active TB
	 o	 b.  Is recommended in patients who received Bacillus Calmette-Guérin 
(BCG) vaccination
	 o	 c. Is more convenient to perform than the T-Spot assay
	 o	 d. Is more sensitive than the tuberculin skin test in all studies
6.  Based on heterogeneous study results, complete right bundle branch block 
(RBBB) in patients with coronary artery disease (CAD) likely confers:
	 o	 a.  The same risk of mortality as CAD patients with incomplete RBBB
	 o	 b. An increased risk of mortality versus CAD patients without RBBB
	 o	 c.  An increased risk of mortality versus CAD patients with left bundle 
branch block
	 o	 d. A decreased risk of mortality versus CAD patients without RBBB
7.  A patient who takes hydrochlorothiazide presents with a sodium level  
of 124 mEq/L. Further testing reveals a serum uric acid level  
of 5.1 mg/dL. This clinical situation is most consistent  
with which of the following conditions?
	 o	 a. Isolated total body water depletion
	 o	 b. Syndrome of inappropriate diuresis
	 o	 c.  Extracellular volume depletion
	 o	 d. Gout
8.  In which one of these acute ischemic stroke patients should  
the blood pressure (BP) be treated?
	 o	 a.  BP of 210/115 mmHg and not receiving tissue plasminogen 
activator (tPA)
	 o	 b. BP of 180/100 mmHg and receiving tPA
	 o	 c. BP of 225/117 mmHg and not receiving tPA
	 o	 d. BP of 160/90 mmHg and receiving tPA
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What is the FPIN Institute?
Simply stated, the FPIN Institute is a collection of modules offered in an independent virtual or onsite 
environment.  You may access a variety of PowerPoint presentations, podcasts, instructional documents, 
handouts, and comprehension quizzes, etc. 
Soon, everyone is going to be talking  
about the FPIN Institute!
Look for the FPIN Institute button on the front page  
of the FPIN website:  www.fpin.org 
Currently we have modules addressing each of our writing projects,  
synthesizing evidence, levels of evidence, and much more.  
Check it out today!
